The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme – New challenges for public health
- 1 December 2015
- journal article
- review article
- Published by Elsevier in Journal of Infection
- Vol. 71 (6) , 611-614
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialThe Lancet, 2014
- Increase in Endemic Neisseria meningitidis Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and WalesClinical Infectious Diseases, 2014
- A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)Human Vaccines & Immunotherapeutics, 2014
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverageVaccine, 2013
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessmentThe Lancet Infectious Diseases, 2013
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trialsThe Lancet, 2013
- The changing and dynamic epidemiology of meningococcal diseaseVaccine, 2012
- Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization SchedulesJAMA, 2012
- Meningococcal carriage by age: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Advances in the Development of Vaccines againstNeisseria meningitidisNew England Journal of Medicine, 2010